Robin Toft Has Been Appointed as the Chief Executive Officer of Curebound

About Curebound

Curebound is a philanthropic organization that fundraises and invests in cancer research with the power to save lives. Through collaborative grants, corporate partnerships, and strategic investments, Curebound's aim is to significantly accelerate better prevention, detection, and treatments for cancer. Headquartered in the major U.S. biotech hub of San Diego, amid 3,000+ life sciences companies, leading health systems, and world-class research institutions, Curebound partners with these organizations to forge interdisciplinary collaboration, foster knowledge sharing, and fund pioneering cancer research. So far, Curebound has funded $43 million in cancer research, awarding 142 study grants for 23 types of pediatric and adult cancers with one vision: cures in our lifetime.

Chief Executive Officer Appointment

Robin Toft has been appointed chief executive officer of Curebound, effective January 1. Toft succeeds founding CEO Anne Marbarger, who will join the Curebound Board of Directors and serve as an advisor to Toft and the leadership team, ensuring continuity as the organization enters its next decade of impact.

Experience and Background

• Built and sold an executive search firm focused on improving cancer care
• Served on the Board of Directors for the American Cancer Society’s San Diego Chapter and the La Jolla Institute of Immunology
• Currently serves on the Board of Directors for the American Cancer Society’s San Diego Chapter and the La Jolla Institute of Immunology
• Established and chaired the nominating governance committee
• Leads the advancement committee

Commitment to Research

Toft is deeply committed to driving research innovation and investing in cancer studies that support Curebound’s vision to find cures in our lifetime. As founding CEO, Anne Marbarger devoted the past decade to advancing innovative cancer research at Curebound’s predecessor organization, Padres Pedal the Cause, followed by five years as the founding CEO of Curebound. She helped conceptualize and oversee the merger of Padres Pedal the Cause and the Immunotherapy Foundation and built enduring partnerships with leading cancer research institutions and corporate supporters to help create what is now Curebound—a powerhouse philanthropic organization.

Future Vision

Toft says she is deeply dedicated to Curebound’s mission and focused on driving continued growth in fundraising, partnerships, and patient impact. "I look forward to embarking on this new journey with Curebound and continuing the legacy that our CEO Anne Marbarger and co-founders Bill and Amy Koman and Fernanda and Ralph Whitworth have created," Toft said. "Together with our dedicated team, supporters and partners, Curebound will continue to fund promising early-stage studies that can change the future of cancer treatment. With federal funding cuts and dozens of vital studies at risk, we must continue to boldly support high-risk, high-reward research led by the brightest scientific minds to bring the next generation of life-saving discoveries to patients."